Consistently, TLR2 ligand Pam3CSK4 application in vivo with transferred tumor antigen (Ag)-specific CD8+ T cells results in enhanced therapeutic efficacy of these CD8+ T cells in tumor models [74, 75]. The gene discussed is CD8A; the disease is neoplasm.